In the BioHarmony Drug Report Database

"Preview" Icon

Onasemnogene abeparvovec

Zolgensma (onasemnogene abeparvovec) is a gene pharmaceutical. Onasemnogene abeparvovec was first approved as Zolgensma on 2019-05-24. It is used to treat spinal muscular atrophy in the USA. It has been approved in Europe to treat spinal muscular atrophy.

 

Trade Name

 

Zolgensma
 

Common Name

 

onasemnogene abeparvovec
 

ChEMBL ID

 

CHEMBL4297240
 

Indication

 

spinal muscular atrophy
 

Drug Class

 

Image (chem structure or protein)

Onasemnogene abeparvovec structure rendering